Prognostic Stage IV Breast Cancer AJCC v8 Recruiting Phase 1 Trials for Lysine (DB00123)

DBCOND0109667 (Prognostic Stage IV Breast Cancer AJCC v8)Recruiting1 IdentifierTitlePurposeDrugs
NCT05098210Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast CancerTreatment
NCT04616248In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid TumorsTreatment